- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07632157
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (MAGNETIC-AF)
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (MAGNETIC-AF)
The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Intravenous magnesium has become a commonly utilized agent in the treatment of cardiac arrhythmias as an adjunct therapy to rate and rhythm control medications, such as its use in atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR). Though its benefit in the treatment of AFF RVR has been well documented, a consensus on the optimal dosing of magnesium has yet to be achieved. Only one randomized, controlled, double-blinded study has investigated the optimal dosing of magnesium. The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of atrial fibrillation or atrial flutter with rapid ventricular response. This study will use flat-dose intravenous metoprolol for rate control to minimize confounders. Additionally, this study will not require a resulted magnesium level prior to treatment in order to avoid delays in patient care.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Marc McDowell, PharmD
- Telefonnummer: (708) 684-1078
- E-post: marc.mcdowell@aah.org
Studera Kontakt Backup
- Namn: Thomas Szwajnos
- E-post: Thomas.Szwajnos@aah.org
Studieorter
-
-
Illinois
-
Oak Lawn, Illinois, Förenta staterna, 60453
- Rekrytering
- Advocate Christ Medical Center Emergency Department (ACMC ED)
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age > 18 years or older
- Able to provide informed consent
- Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
- Metoprolol as rate control agent
- English speaking
Exclusion Criteria:
- Hemodynamically unstable patients (SBP <90, MAP <65)
- Impaired consciousness
- Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
- Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
- Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
- Acute myocardial infarction
- Contraindications to magnesium sulfate (including myasthenia gravis)
- Allergy or sensitivity to any study drugs
- Previously enrolled in this trial during a different patient encounter
- Withdrew from study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Experimental Arm One, Magnesium Sulfate 2g followed by metoprolol 5 mg
Study drug (Magnesium Sulfate 2 gram/50ml 0.9% NaCl) will be administered over a time interval of 15 minutes. Immediately after study drug administration, intravenous metoprolol 5 mg will be administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of study drug will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity. |
Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Andra namn:
|
|
Experimentell: Experimental Arm Two, Magnesium Sulfate 4g followed by metoprolol
Study drug (Magnesium Sulfate 4 gram/50ml 0.9% NaCl) will be administered over a time interval of 15 minutes. Immediately after study drug administration, intravenous metoprolol 5 mg will be administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of study drug will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity. |
Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Andra namn:
|
|
Placebo-jämförare: Control Arm, normal saline followed by metoprolol
50ml 0.9% NaCl will be administered over a time interval of 15 minutes. Intravenous metoprolol 5 mg will be immediately administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of saline will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity. |
The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Ventricular rate control
Tidsram: Within the first 2 hours of intravenous magnesium administration
|
Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of < 120 beats per minute. |
Within the first 2 hours of intravenous magnesium administration
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mean change in heart rate
Tidsram: up to 24 hours after magnesium infusion
|
Mean change in heart rate after the administration of magnesium sulfate |
up to 24 hours after magnesium infusion
|
|
Incidence of hypotension
Tidsram: At 1 and 2 hours after magnesium administration
|
Systolic blood pressure < 90 or MAP < 65 |
At 1 and 2 hours after magnesium administration
|
|
Incidence of bradycardia
Tidsram: At 1 and 2 hours after magnesium administration
|
Heart rate < 60 beats per minute |
At 1 and 2 hours after magnesium administration
|
|
Mean time to achieve goal heart rate
Tidsram: at 2 hours
|
Mean time to achieve goal heart rate at 2 hours |
at 2 hours
|
|
Rate of conversion
Tidsram: 2 hours after administration of magnesium
|
Rate of conversion to normal sinus rhythm |
2 hours after administration of magnesium
|
|
Clinical need for rescue medication administration
Tidsram: 2 hours from metoprolol administration
|
Dose of rescue medications given (magnesium and metoprolol) |
2 hours from metoprolol administration
|
|
Mean change in heart rhythm
Tidsram: up to 24 hours after magnesium infusion
|
Mean change in heart rhythm after the administration of magnesium sulfate |
up to 24 hours after magnesium infusion
|
|
Clinical need for rescue medication administration
Tidsram: 2 hours from metoprolol administration
|
Route of administration (IV or PO) for rescue medications (magnesium and metoprolol), if administered. |
2 hours from metoprolol administration
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Marc McDowell, PharmD, Advocate Christ Medical Center Emergency Department
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IRB00146620
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .